Scarica l'app Stockscreener
54.31
0.15%
0.08
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AKRO Giù?
Forum
Previsione
Precedente Chiudi:
$54.23
Aprire:
$54.28
Volume 24 ore:
1.12M
Relative Volume:
0.53
Capitalizzazione di mercato:
$4.47B
Reddito:
-
Utile/perdita netta:
$-269.44M
Rapporto P/E:
-14.48
EPS:
-3.75
Flusso di cassa netto:
$-262.63M
1 W Prestazione:
+0.11%
1M Prestazione:
+0.95%
6M Prestazione:
+12.33%
1 anno Prestazione:
+74.07%
Intervallo 1D:
$54.26
$54.35
Intervallo di 1 settimana:
$54.22
$54.41
Portata 52W:
$21.34
$58.40
Akero Therapeutics Inc Stock (AKRO) Company Profile
Nome
Akero Therapeutics Inc
Settore
Industria
Telefono
650-487-6488
Indirizzo
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
Confronta AKRO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AKRO
Akero Therapeutics Inc
|
54.31 | 4.46B | 0 | -269.44M | -262.63M | -3.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-04 | Ripresa | H.C. Wainwright | Buy |
| 2025-08-04 | Iniziato | TD Cowen | Buy |
| 2025-01-30 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-01-27 | Reiterato | H.C. Wainwright | Buy |
| 2024-11-18 | Iniziato | Citigroup | Buy |
| 2024-04-22 | Ripresa | BofA Securities | Neutral |
| 2023-09-19 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-08-28 | Iniziato | UBS | Buy |
| 2023-01-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-14 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2021-10-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-10 | Iniziato | BofA Securities | Buy |
| 2021-02-26 | Iniziato | Guggenheim | Buy |
| 2020-09-10 | Iniziato | Morgan Stanley | Overweight |
| 2020-07-20 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-07 | Iniziato | Chardan Capital Markets | Buy |
| 2020-07-01 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-02 | Iniziato | H.C. Wainwright | Buy |
| 2020-02-10 | Iniziato | Canaccord Genuity | Buy |
| 2019-07-15 | Iniziato | Evercore ISI | Outperform |
| 2019-07-15 | Iniziato | JP Morgan | Overweight |
| 2019-07-15 | Iniziato | Jefferies | Buy |
| 2019-07-15 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Akero Therapeutics Inc Borsa (AKRO) Ultime notizie
Intech Investment Management LLC Sells 16,635 Shares of Akero Therapeutics, Inc. $AKRO - MarketBeat
Will Akero Therapeutics Inc. (0K4) stock outperform value peersPortfolio Profit Report & Daily Oversold Bounce Ideas - newser.com
Halper Sadeh LLC Encourages SEE, AXTA, SEMR, AKRO Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero Therapeutics, Inc.AKRO - Business Wire
What dividend safety rating applies to Akero Therapeutics Inc. (0K4) stockWeekly Investment Report & Free Reliable Trade Execution Plans - newser.com
Is Akero Therapeutics Inc. stock a smart buy before Fed meetingIndex Update & Risk Controlled Daily Trade Plans - newser.com
Is Akero Therapeutics Inc. (0K4) stock a top pick for value investorsPrice Action & Reliable Price Breakout Signals - newser.com
Is Akero Therapeutics Inc. stock a top pick in earnings seasonTreasury Yields & Daily Profit Focused Screening - newser.com
Can Akero Therapeutics Inc. (0K4) stock deliver strong annual returnsMarket Growth Report & Real-Time Volume Analysis - newser.com
Is Akero Therapeutics Inc. (0K4) stock prepared for digital transitionJuly 2025 Setups & Free Weekly Chart Analysis and Trade Guides - newser.com
Is Akero Therapeutics Inc. stock a buy before product launches2025 Dividend Review & Technical Entry and Exit Alerts - newser.com
Why Akero Therapeutics Inc. (0K4) stock attracts HNW investorsJuly 2025 Final Week & Expert Approved Trade Ideas - newser.com
Is Akero Therapeutics Inc. stock attractive for growth ETFsQuarterly Profit Summary & AI Enhanced Trading Signals - newser.com
Why Akero Therapeutics Inc. stock is recommended by analystsQuarterly Trade Review & Short-Term High Return Strategies - newser.com
Is Akero Therapeutics Inc. stock supported by innovation pipelineJuly 2025 Reactions & Free High Accuracy Swing Entry Alerts - newser.com
Is Akero Therapeutics Inc. stock attractive for income investorsProduct Launch & Advanced Technical Signal Analysis - newser.com
Bank of New York Mellon Corp Increases Stake in Akero Therapeutics, Inc. $AKRO - MarketBeat
Heatmap analysis for Akero Therapeutics Inc. and competitors - newser.com
Is Akero Therapeutics Inc. (0K4) stock a contrarian opportunityPortfolio Value Report & Long Hold Capital Preservation Tips - newser.com
Will Akero Therapeutics Inc. stock keep outperforming rivals2025 Market WrapUp & Daily Profit Maximizing Trade Tips - newser.com
What drives Akero Therapeutics Inc stock priceCurrency Fluctuation Impact & Start Building Capital with Zero Risk - earlytimes.in
Akero Therapeutics shares breakthrough MASH treatment data - Traders Union
Akero Therapeutics, Inc. (NASDAQ:AKRO) Given Average Rating of "Hold" by Brokerages - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Takes $2.21 Million Position in Akero Therapeutics, Inc. $AKRO - MarketBeat
How rising interest rates impact Akero Therapeutics Inc. stock2025 Bull vs Bear & Consistent Return Investment Signals - newser.com
Will Akero Therapeutics Inc. (0K4) stock rise with strong economyTrade Analysis Report & Daily Oversold Bounce Ideas - newser.com
Using RSI to spot recovery in Akero Therapeutics Inc.July 2025 Decliners & Smart Investment Allocation Insights - newser.com
Akero Therapeutics Inc Azioni (AKRO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.38%
1.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):